Clinical Case Alcoholic Liver disease Prepared By: Tasnim Kullab

Slides:



Advertisements
Similar presentations
Learning objectives To understand the pathophysiologic basis for vasoactive therapies for HRS To become familiar with the diagnostic criteria for HRS To.
Advertisements

Hepatitis B: Epidemiology and Public Health Issues
Dr. David Pearson Gastroenterology, Victoria.  None relevant to this presentation.
Copyright Alcohol Medical Scholars Program A Clinical Guide To Assessing Alcohol Use And Problems Andrea DiMartini M.D. University of Pittsburgh.
Clinical Case Conference
Liver Function Tests (LFTs)
LIVER PATHOLOGY LAB MHD II January 20, Case 1 Describe the low power findings.
1 CLINICAL CHEMISTRY-2 (MLT 302) LIVER FUNCTION AND THE BILIARY TRACT LECTURE FOUR Dr. Essam H. Aljiffri.
Toxic Hepatocellular Injury Mike Contarino, MD Internal Medicine and Pediatrics 1/22/10.
Acute liver failure Tutorial Ayman Abdo MD, FRCPC.
Liver disease Prepared by: Siti Norhaiza Bt Hadzir.
MLAB 2401: Clinical Chemistry Keri Brophy-Martinez Alterations in Liver Function.
I n t e g r i t y - S e r v i c e - E x c e l l e n c e Headquarters U.S. Air Force 1 Clinical Assessment of Alcohol Use.
CIRRHOSIS OF LIVER PORTAL HYPERTENSION HEPATIC ENCHEPALOPATHY
By Abdul Hameed Jan Alcoholic Hepatitis. Outline Outline: 1.Intro 2.Definition 3.Pathogenesis 4.Symptoms 5.Clinical signs 6.Treatment 7.Complications.
 Hepatic Pathology and Respiratory System Topics in Human Pathophysiology Fall 2011 Gilead Drug Safety and Public Health.
Prof JH van Zyl Central role of liver in drug metabolism 02. Principal reactions in drug metabolism 03. Electron flow pathway in the microsomal.
NYU Medical Grand Rounds Clinical Vignette Alexander Jow, PGY-3 February 21, 2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Liver Function Tests. Tests Based on Detoxification and Excretory Functions.
Biochemical markers in disease diagnosis
The Use of Mortality Data to Improve Risk Assessment CTHOLUA Seminar February, 2011 Robert Stout, Ph.D., President and Director Clinical Reference Laboratory.
Cirrhosis Dr. Meg-angela Christi M. Amores. Cirrhosis a histopathologically defined condition – pathologic features consist of the development of fibrosis.
A 57-year-old man presents with fatigue for several months. He underwent a blood transfusion with several units in 1982 after car accident. Physical examination.
Dr. Ravi kant Assistant Professor Department of General Medicine.
Biochemical markers for diagnosis of diseases and follow up Dr. Rana Hasanato Associate professor and consultant Head of clinical chemistry department.
Biochemical markers for diagnosis and follow up of disease
陳京瑜.  In the assessment of many different diseases  Red blood cell production and destruction  Diagnose infection, allergies, and problems with blood.
PK 1 조 :: 조재완 DDx of jaundice. Jaundice: Introduction Jaundice - Yellowish discoloration : deposition of bilirubin – Serum hyperbilirubinemia – Liver.
Alcoholic Hepatitis Miriam Nojan PGY-2 April 2016.
Acute Liver Failure Tutorial Ayman Abdo. Objectives After the discussion in this educational exercise, I want you to be able to : Identify common causes.
Alcohol related Liver Disease
Alcoholic Liver Disease Prof.Dr. Khalid A. Al-Khazraji MBCHB, CABM, FRCP, FACP Baghdad medical college
HBV & HCV induced Liver Cirrhosis Iradj Maleki MD Gut & Liver Research Center Mazandaran University of Medical Sciences.
Intern Report Patient Presentation  55yM no PMH presenting with worsening abdominal pain for 2-3 days. Describes pain as diffuse, non-radiation,
Case Report AK Liver biopsy total length 6 mm suggestiv for
Drug Induced Liver Disease Tutoring
Alcoholic liver disease and non-alcoholic fatty liver disease
Liver Function Tests (LFTs)
Recurrent hepatitis with Halogenated Anesthetics
Eosinophilic Cholangiopathy
Liver Disease tutoring Part 1
Liver Function Tests (LFTs)
Liver Disease tutoring Part 2
SMOKING AND HISTOLOGICAL STAGE OF CHRONIC VIRAL HEPATITIS
is caused by the Hepatitis A virus (HAV)
Hepatopancreatobiliary
BY: Asmaa Alastal. wafaa hanouna. Salma abu taha. .Sara shaban
HCV & liver transplantation
biochemical markers for diagnosis and follow up of diseases
Hemangioendothelioma
Chronic viral hepatitis type B with “ground glass” cells
Successful TACE for HCC
Alcoholic cirrhosis and acute alcoholic fatty liver with cholestasis
Non-alcoholic steatohepatitis with positive ANA
Orthotopic liver transplant, recurrent non-alcoholic steatohepatitis
Comorbidity NASH/HCV and HCC
Alcoholic foamy degeneration with early alcoholic cirrhosis
Acute viral hepatitis type C
Successful Tace in Patient with large HCC
Liver “Function” Test 2013 Mini-Lecture
Chapter 3 Fatty Liver Diseases 1 Alcoholic steatosis Case 3.1.
Determination of the enzyme ALT (SGPT) & AST activity in serum by enzymatic method using Biophotometer.
Alcoholic hepatitis with diffuse interstitial fibrosis
Grand Rounds: Alcoholic Hepatitis
Gastrointestinal Pathology 3
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Alcoholic Hepatitis (1)
CLINICAL SOLVING PROBLEM
PRESENTER: Quynh vu, pgy-2
LFTs and Bloods Laz.
Presentation transcript:

Clinical Case Alcoholic Liver disease Prepared By: Tasnim Kullab Haneen Akella Abeer Jendia

50 M with no PMH admitted with 1 week h/o jaundice, abdominal pain and distention; also with increasing fatigue. + h/o chronic alcohol abuse, attempted AA without success Recent alcohol binging over the past 2 months especially on weekends-drinks a fifth of whiskey/day

Clinical Case None None Single businessman NKDA Medications: None Social History: Single businessman + ETOH-multiple attempts at rehab No IVDU No tobacco PMH/PSH: None Allergies: NKDA FH: No FH of liver disease 3

Laboratory Finding albumin 2.5 (3.5-5.2 g/dL) AST 185 (10-59U/L) ALT 50 (13-40U/L) Alk phos 90 (53-128 IU/L) amylase 150 (27-131 U/L) lipase 230 (12-70 U/L) Ascites: albumin <1, 150 WBC (10% segs) RUQ U/S: large ascites, nodular liver, mild splenomegaly 4

Alcoholic Liver Disease Affects 1% of the US Population Ranges from simple steatosis, alcoholic hepatitis, to cirrhosis Accounts for >12000 deaths/yr 2nd most frequent indication for OLT

Alcoholic Liver Disease-Spectrum

Alcoholic Hepatitis Clinical syndrome of jaundice and liver failure, generally with chronic alcohol use (mean ~100 gm/day) Common symptoms apart from jaundice include fever, ascites, cachexia, RUQ pain and HE Risk factors include amount of alcohol ingested (not a linear relationship); increased risk with female sex Genetic factors (increased risk in children of alcoholics) Protein calorie malnutrition Concomitant viral hepatitis (HCV)

Pathogenesis Oxidative metabolism to acetaldehyde generates reactive oxygen species, which induce lipid peroxidation, causing hepatocellular death via necrosis/apoptosis Increased endotoxin levels due to intestinal permeability leading to increased pro-inflammatory cytokines by activating Kupffer cells (TNF α levels are higher in pts with AH than in pts with inactive cirrhosis)

Lucey M et al. N Engl J Med 2009;360:2758-2769

Diagnosis Elevated AST and ALT ( rarely > 300 IU/ml) AST/ALT > 2:1 Increased GGT -independent of liver disease Leukocytosis with neutrophilia Increased MCV (80-100% pts) –due to ETOH induced marrow toxicity, B12/folate deficiency Elevated creatinine-ominous sign (HRS) Carbohydrate deficient transferrin Elevated IgA levels Hyperbilirubinemia, coagulopathy, TCP

Histology

Assessing Illness Severity Maddrey’s Discriminant Function MELD Glasgow Alcoholic Hepatitis Score ECBL Lille model

Therapy-Corticosteroids Most intensely studied yet most hotly debated Block cytotoxic as well as inflammatory pathways (inhibit NF-KB, decrease TNF α levels) Decrease intracellular adhesion molecule 1 in sinusoidal cells-inhibit leukocyte activation Prednisolone 40mg daily recommended in pts CONTRAINDICATIONS: -Infection/sepsis -GI bleed -Renal insufficiency

Liver Transplantation AH is considered a contraindication to transplantation and 6 months of abstinence is recommended as minimal listing criterion although small studies have shown no worse outcomes in pts with AH Recidivism rates range from 11-50% at 3-5 years post-transplantation